surmount-1 tirzepatide weight loss nondiabetic for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Clinical trials of subcutaneous tirzepatide
Description
These charts follow the standard tirzepatide escalation protocol with 2.5mg increases every four weeks minimum
There is no one way to switch that is recommended for everyone
Patients should maintain adequate hydration, particularly during initial titration
Hence, the dynamic study of incretin drugs may be the center of future research
You may inject them in the same body region, but do not inject them next to each other
